hlx55
mAbexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04169178)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04169178 | Phase 1 | Nov 30, 2019 | Government of Taiwan, Henlix, Inc, National Cheng Kung University, Taipei Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of Taiwan | Government | 1 | 0 | 1 | 2019 |
| Henlix, Inc | For profit | 1 | 1 | 1 | 2019 |
| National Cheng Kung University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1